Drug Education Guide

Durvalumab (Patient)

Immunotherapy Monoclonal antibody PD-L1 inhibitor

Durvalumab (Patient)

Immunotherapy Monoclonal antibody PD-L1 inhibitor
Light Sensitive Fall Risk
Medication Basics

Drug Name

Durvalumab (Brand names: Imfinzi®)

Purpose / Indication

Used to treat certain cancers, including lung cancer, biliary tract cancer, hepatocellular carcinoma, and other approved oncology indications as directed by the care team.

Dosage & Administration

Dose Schedule

Administered as an intravenous infusion on a schedule determined by cancer type, combination regimen, weight, and protocol; common schedules include every 2, 3, or 4 weeks.

Route

IV (Intravenous)

Timing Considerations

Treatment is given in cycles. The infusion schedule is determined by the oncology team and may change if side effects occur.

Time of Day

Flexible

Special Instructions

Keep all appointments and tell your care team about new symptoms before each treatment.

Injection Techniques

This medicine is given by trained healthcare professionals through an IV line.

Mechanism of Action

Mechanism

This medicine helps your immune system find and fight cancer cells by blocking a pathway that cancer cells may use to avoid immune detection.

13 More Sections — Members Only

Free membership unlocks the complete guide.

  • Side Effects
  • Drug Interactions
  • Contraindications
  • Monitoring
  • Adherence
  • + 8 more…
Was this guide helpful?